As we approach the end of the year, we reach an important milestone with the completion of our acquisition of three manufacturing sites from Novo Holdings. This follows the finalisation of Novo Holdings’ acquisition of Catalent Pharma Solutions, a global contract development and manufacturing organisation headquartered in New Jersey (US). “We are very pleased with the completion of the acquisition. The three sites will expand our manufacturing capacity at scale and speed, while complementing our ongoing significant internal supply chain expansions. The acquisition will enable us to reach significantly more people living with serious chronic diseases”, says our CEO and president Lars Fruergaard Jørgensen. Curious to know more? Get all the details in our company announcement here https://lnkd.in/gu4MH2U #NovoNordisk #DrivingChange
Novo Nordisk
Produktion af lægemidler
Driving change to defeat serious chronic diseases, built upon our heritage in diabetes.
Om os
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
- Websted
-
https://www.novonordisk.com
Eksternt link til Novo Nordisk
- Branche
- Produktion af lægemidler
- Virksomhedsstørrelse
- Over 10.001 medarbejdere
- Hovedkvarter
- Bagsværd
- Type
- Aktieselskab
- Grundlagt
- 1923
- Specialer
- Pharmaceuticals, Insulin, obesity, Rare Diseases og Diabetes
Beliggenheder
Medarbejdere hos Novo Nordisk
-
Thomas Røygaard
PMO | Digital Transformation | Leading Program, Project and Portfolio Management | Governance | Change Management
-
Naras Eechambadi
Board Director | Executive Coach | Global Leader in Data & AI | C-Suite Executive
-
Sören Meelby
Digital Healthcare Evangelist | Cultivating Partnerships for Collective Impact & Social Good
-
Henrik Vestergaard
Opdateringer
-
Season's Greetings from us to all of you! Before we step into 2025, let’s look back on an eventful 2024 together. We’re excited to share more moments with you in the new year! 💙 #NovoNordisk #DrivingChange
-
We are launching a 2-week minimum caregiver leave for all employees globally from the beginning of the new year. Because we believe that supporting our people when they need it most isn't just a benefit— it's a fundamental part of who we are. A caregiver is any colleague who provides physical, psychological, or emotional support to their dependent who has a serious health condition. This is important, so we all have the opportunity to achieve a good work/life balance while managing multiple priorities. Especially when life is difficult. Kathy, our US colleague and a benefits manager, leaned on our caregiver benefits, which were already in place in the US. The leave gave her the time and space to prioritise what truly mattered: being there for her husband, William, during his battle with cancer. “Our benefits allow us to be human to one another. They allow us the grace to do what we have to do – and that means understanding that there are times in our lives when work should not interfere with that." Thank you, Kathy, for sharing your story. We know how much it means to you and your work to share this benefit with as many as possible. Read more about the caregiver leave here: https://lnkd.in/dnGzZN8Y #Caregiver #EmployeeBenefits #NovoNordisk
-
We're investing in a new production facility in Odense, Denmark - the first new site we’ve built in Denmark this century. The new facility will help produce treatments for rare diseases, including haemophilia, using advanced technology and innovation. The site will also be in sustainable design with a commitment to preserve the nature in the area. Scheduled for completion in 2027, it will create 400 permanent jobs and support growing global demand for life-changing medicines. We’re proud to expand our heritage in Denmark and look forward to contributing to the community in Odense! Learn more here 👉 https://lnkd.in/gu4MH2U #NovoNordisk #DrivingChange #Production #Innovation
-
In the early 2000s, three of our scientists embarked on a groundbreaking journey to reduce the treatment burden for people living with type 2 diabetes. Their goal was simple. They wanted to develop a treatment that only required to be injected once every week, instead of once every day, and that was a huge scientific challenge. With relentless dedication, experimentation, and hundreds of compounds screened they arrived at a technology suitable for engineering a once-weekly compound. Today, we proudly celebrate Jesper Lau, Thomas Kruse, and Paw Bloch as co-recipients of the 2024 Inventor of the Year Award by the IPO Education Foundation. Please join us in celebrating the three inventors! #DrivingChange #LifeSciences #IPOEFAwards #InventorOfTheYear #IntellectualProperty
-
We are thrilled by the high number of applications we have received for our Global Graduate Programme 🌎🎓 Young talents from across the globe have applied for the 86 graduate positions we have available in 2025. Applications are now closed and we want to thank all applicants for the overwhelming potential and enthusiasm to join our company. While the graduate positions are limited, you can register your interest on our Global Talent Hub to stay up to date with other early career opportunities and relevant vacancies here 👉https://lnkd.in/eR8nthDX
-
Can we grow while embracing sustainability? Yes! But growing while reducing impact is also a significant challenge. This week TIME has published its first ever ranking of the World's Best Companies in Sustainable Growth. This ranking reconfirms that strong financial and sustainability performance go hand in hand. Acknowledging the efforts of companies who prioritise sustainable practices reinforces our joint commitment to do more with less. Read more about the TIME ranking and the best cases here 👉 https://lnkd.in/esms_43j
-
This #DiabetesAwarenessMonth, colleagues worldwide have shown support to the diabetes community by arranging events, talks and fundraising walks. Together, we are committed to driving change and improving diabetes care for generations to come 💙 Let us know how you marked Diabetes Awareness Month in the comments below 👇 #NovoNordisk #DrivingChange #WorldDiabetesDay
-
+ 4
-
Last call! Apply for Novo Nordisk's Graduate Programme before 30 November 2024! 🎓🚀 Our two-year programme offers three to four rotations around the world across 18 different graduate tracks spanning technology, pharmaceutical development, supply chain, and more. Dive deep into the Novo Nordisk value chain and grow in ways you never imagined. 🌍 Apply before 30 November and join us in making a real difference! 👉 https://brnw.ch/21wOPQA
-
Is it wishful thinking that all children can eat well and be active? We don’t think so, and today we’re marking five years of collaboration with UNICEF on creating healthier environments for children worldwide 💙 Find out more here: https://lnkd.in/eXjdDZ2j #WorldChildrensDay #UNICEF #NovoNordisk #Prevention #HealthEquity
Tilsvarende sider
Aktie
NVO
NYSE
20 minutters forsinkelse
87,37 US$
-1,34 (-1,511 %)
- Åbningspris
- 88,9
- Lavpunkt
- 87,07
- Højdepunkt
- 88,98
Data fra Refinitiv
Få flere oplysninger påFinansiering
Seneste runde
Post IPO-egenkapital22.000.000,00 US$